Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month High – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $32.89 and last traded at $32.50, with a volume of 368184 shares trading hands. The stock had previously closed at $32.00.

Wall Street Analyst Weigh In

ORKA has been the subject of a number of recent analyst reports. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective for the company. Barclays started coverage on shares of Oruka Therapeutics in a report on Monday, October 13th. They set an “overweight” rating and a $48.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 8th. Guggenheim assumed coverage on shares of Oruka Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Piper Sandler began coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.67.

Oruka Therapeutics Trading Up 1.6%

The company has a market capitalization of $1.57 billion, a P/E ratio of -17.11 and a beta of -0.39. The firm’s 50 day moving average price is $29.40 and its two-hundred day moving average price is $21.81.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. Analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $30.61, for a total value of $214,270.00. Following the completion of the transaction, the insider directly owned 1,518 shares in the company, valued at approximately $46,465.98. The trade was a 82.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.69% of the stock is currently owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Several large investors have recently made changes to their positions in ORKA. Financial Enhancement Group LLC bought a new position in Oruka Therapeutics in the third quarter valued at about $631,000. B Group Inc. boosted its stake in shares of Oruka Therapeutics by 28.8% in the 2nd quarter. B Group Inc. now owns 75,000 shares of the company’s stock valued at $841,000 after purchasing an additional 16,785 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock valued at $7,932,000 after purchasing an additional 354,821 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Oruka Therapeutics by 10.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after purchasing an additional 58,117 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in Oruka Therapeutics by 40.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after purchasing an additional 292,421 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.